Top

Published in:

01-10-2013 | Research Article

Study of survival in patients with malignant lung lesions treated with radiofrequency

Authors: J. M. Galbis Caravajal, J. Jornet Fayos, M. Cuenca Torres, E. Mollá Olmos, M. Estors Guerrero, F. Sánchez García, N. J. Martinez Hernandez, R. Esturi Navarro, A. Pastor del Campo, M. Vaño Molina

Published in: Clinical and Translational Oncology | Issue 10/2013

Abstract

Objective

To report on the survival of a series of patients with primary and metastatic lung tumours treated with radiofrequency (RF). Four years ago we published our preliminary experience with the use of this technique.

Materials and methods

For a period of 8 years we have treated 59 patients (by means of a total of 70 procedures) with primary or metastatic pulmonary neoplastic lesions, which fulfilled inclusion criteria to perform the technique. They were in all cases non-surgical lesions that had been either previously treated or not. The technique was performed in the radiology suite, under conscious analgo-sedation. We treated primary pulmonary lesions, neoplastic recurrences, or metastases with curative or palliative intention (pain management).

Results

Current global survival rate is 19 patients (32 %) with a mean of 26.61 ± 3.17 months (range: 20.38 ± 32.83) and a median of 16.00 ± 3.57 (range: 8.99–23.00). If we establish the difference between primary and metastatic tumours, mean survival is 27.62 ± 4.12 months in primary tumours (median: 16.00) vs. 24.65 ± 4.47 months in metastatic tumours (median: 16.00). When we studied the survival in those cases with a curative intent, mean survival in primary tumours was 30.97 ± 4.57 months (median: 21.00) vs. 25.14 ± 4.68 (median: 16.00) months in metastatic tumours.

Conclusions

RF ablation of lung lesions is a minimally invasive procedure that is useful in primary tumours (especially in stage I) and metastatic ones. RF has proven its usefulness in the multidisciplinary treatment of this pathology due to the low incidence of serious complications and survival obtained, considering that patients are elderly with significant comorbidity.

Healey T, Dupuy D (2011) Radiofrequency ablation. Cancer J 17:33–37PubMedCrossRef

Sharma A, Moore W, Lanuti M, Shepard JA (2011) Radiofrequency ablation and cryoablation of lung tumours. J Thorac Imaging 26:162–174PubMedCrossRef

Pastorino U, Buyse M, Friedel G et al (1997) Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113:37–49CrossRef

Lanuti M, Sharma A, Digumarthy SR et al (2009) Radiofrequency ablation for treatment of medically inoperable stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 137:160–166PubMedCrossRef

Beland MD, Wasser EJ, Mayo-Smith WW et al (2010) Primary non-small-cell lung cancer: review of frequency, location and time of recurrence after radiofrequency ablation. Radiology 254:301–307PubMed

Bradley B, Thornton R, Solomon S (2010) Ablation of pulmonary malignancy: current status. J Vasc Interv Radiol 21:S223–S232CrossRef

Eward S (2006) Controversies between surgical and percutaneous radiofrequency ablation. Eur J Surg Oncol 32:3–5CrossRef

Gandhi NS, Dupuy DE (2005) Image-guided radiofrequency ablation as a new treatment option for patients with lung cancer. Semir Roentgenol 40:171–181CrossRef

Pennathur A, Abbas G, Schuchert M, Landreneau R, Luketich J, Pennathur A, Abbas G, Schuchert M, Landreneau R, Luketich J et al (2010) Image-guided radiofrequency ablation for the treatment of early-stage non-small cell lung neoplasm in high-risk patients. Semin Thoracic Surg 22:53–58CrossRef

10.

Galbis Caravajal JM, Pallardó Calatayud Y, Revert Ventura A, Sales Badía JG, Esturi Navarro R, Cuenca Torres M (2008) Ablación mediante radiofrecuencia guiada por tomografía computerizada de las lesiones pulmonares malignas. Arch Bronconeumol 44(7):364–370PubMedCrossRef

11.

Scott WJ, Howington J, Feigenberg S et al (2007) Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(Suppl):234S–242SPubMedCrossRef

12.

Dupuy DE (2011) Image-guided thermal ablation of lung malignancies. Radiology 260(3):633–655PubMedCrossRef

13.

Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer by the Lung Cancer Study Group. Ann Thorac Surg 60:615–623PubMedCrossRef

14.

Miyamoto T, Baba M, Sugane T et al (2007) Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2:916–926PubMedCrossRef

15.

Zierhut D, Bettscheider C, Schubert K et al (2001) Radiation therapy of stage I and II non-small cell lung cancer (NSCLC). Lung Cancer 34(Suppl 3):S39–S43PubMedCrossRef

16.

Grills IS, Mangona VS, Welsh R et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28:928–935PubMedCrossRef

17.

Bilfinger TV, Baram D (2008) Sublobar resection in non-small cell lung carcinoma. Curr Opin Pulm Med 14:292–296PubMedCrossRef

18.

Zemylak A, Moore WH, Bilfinger Th (2010) Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer. J Am Coll Surg 211:68–72CrossRef

19.

El-Sherif A, Fernando HC, Santos R et al (2007) Margin and local recurrence after sublobar resection of non-small cell lung cancer. Ann Surg Oncol 14:2400–2405PubMedCrossRef

20.

Eradat J, Abtin F, Gutierrez A, Suh R (2011) Evaluation of treatment response after non operative therapy for early-stage non-small cell lung carcinoma. Cancer J 17:38–48PubMedCrossRef

21.

Treasure T (2007) Pulmonary metastasectomy: a common practice based on weak evidence. Ann R Coll Surg Engl 89:744–748PubMedCrossRef

22.

King G, Glenn D, Clark W et al (2004) Percutaneous radiofrequency ablation of pulmonary metastases in patients with colorectal cancer. Br J Surg 91:217–223PubMedCrossRef

23.

Pua B, Thornton R, Solomon S (2010) Ablation of pulmonary malignancy: current status. J Vasc Interv Radiol 21:S223–S232PubMedCrossRef

24.

Sano Y, Kanazawa S, Gobara H et al (2007) Feasibility of percutaneous radiofrequency ablation for intrathoracic malignancies: a large single-center experience. Cancer 109:1397–1405PubMedCrossRef

25.

Jornet J, Pallardó Y, Revert AJ, Galbis JM, Mollá E, Sales G (2009) Drenaje de neumotórax iatrogénico con catéter de calibre pequeño. Radiología 51(1):57–62PubMedCrossRef

26.

Pouliquen C, Kabbani Y, Saignac P, Gékière JP, Palussière J (2011) Radiofrequency ablation of lung tumours with the patient under thoracic epidural anaesthesia. Cardiovasc Intervent Radiol 34:S178–S181PubMedCrossRef

27.

Pennathur A, Abbas G, Gooding WE, Schuchert M, Gilbert S, Christie N, Landreneau R et al (2009) Image guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service. Ann Thorac Surg 88:1601–1608PubMedCrossRef

28.

Pennathur A, Luketich JD, Abbas G et al (2007) Radiofrequency ablation for stage I non-small cell lung neoplasm. J Thorac Cardiovasc Surg 134:857–885PubMedCrossRef

29.

Baisi A, Raveglia F, De Simone M, Cioffi U (2012) Recurrence after radiofrequency ablation for stage I non-small cell lung cancer. Ann Thorac Surg 94(5):1788–1789PubMedCrossRef

Title: Study of survival in patients with malignant lung lesions treated with radiofrequency
Authors: J. M. Galbis Caravajal
J. Jornet Fayos
M. Cuenca Torres
E. Mollá Olmos
M. Estors Guerrero
F. Sánchez García
N. J. Martinez Hernandez
R. Esturi Navarro
A. Pastor del Campo
M. Vaño Molina
Publication date: 01-10-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 10/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1011-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2013

Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences

Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer

CUG-binding protein 1 (CUGBP1) expression and prognosis of non-small cell lung cancer

Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis

Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer